NTLA Intellia Therapeutics Inc

$NTLA and another 510 k for Caty 29 sept 205.192 30 sept 466.956 1 oct 410.911 2 oct. 511.697 Totals: 1.594.756 shares.

$NTLA A few thoughts about Cathie Woods First, I appreciate the posters here who give updates on CW's purchases of NTLA. CW's detractors like to say that her ownership of an equity is some kind of reverse indicator. Slightly humorous, but I don't trust your motives. She has had ups and downs in her plays, as everyone knows. But she is still actively in the game. Being trusted with the management of lots of other people's dough, she continues to pour millions into NTLA. Is this the desperate doubling down of a loser? I think not. CW believes Intellia possesses disruptive tech that will be a transformative force in medicine. I believe she would only be maintaining and continuously adding to her NTLA bet based on rigorous, up to the minute research and intimate knowledge of the whole Intellia op that verifies her belief. So, scoff away, you CW scoffers. I do not trust your motives. And please keep posting, CW followers. I'm betting with her.

$NTLA Barclays analyst Gena Wang puts a $8 PT on Intellia with the main reason being that the ''market is already fully occupied by competitors'' and that there is no room for Intellia anymore. However, this is where every negative analyst misses the point. Intellia's Lonvo-z is a CURE rather than just another prophylactic treatment. A one time injection and then, as a HAE patient, you are DONE for the rest of your life. No more injections, no more panic when going on vacation thinking you forgot your medication. NO MORE SWELLINGS. Another point she mentioned is that Lonvo-z adoption would probably be ''very slow''. More than 90% of HAE patients is willing to try other therapies given the big burden the disease is having on their lives. Intellia has already hired several medical personnel to spread the word and make patients aware of the fact that there is a permanent treatment on the way for some time now. There will be HAE patients waiting in line for the Lonvo-Z one time therapie!

$NTLA So the same analyst that gave NTLA a $14 price target last year bear before BLA submission is now giving a target of 8. Barclays want in, but they want in at a cheap price. I hope it backfires

$NTLA The risks here are 110% priced in. The upside is about 10% priced in. So owning NTLA is both scary and exciting.

$NTLA Morgan Stanley Intellia fireside chat sept14th: All participants HAELO,1,2,3 are now LTP free and HAE didn,t return. That,s about 100 patients. Within 6 months after launch Lonvo-Z 60 procent of all HAE patiënts will be coveraged by payers. That means 4500 patiënts in total. A big pool of patients. Let,s see how many want to sign in for treatment. Talks with payers are going well The commercial set up is almost ready and working to set up ATC,s.

$NTLA 12-14 november is the ACAAI conference. Intellia published several pressrelases around that conference. What we already know: this time Intellia reserved 1 booth and 2 slots for presentations. Via LARVOL we have a direction what it could be: Attack-free/LTP-free en Four-year durability/safety. 6 oktober is closing date for deadline late-breaking abstracts. Prepare for excellent data👍

$NTLA I’m very hopeful for this company’s future, but I’ve never been a fan of Cathie Wood and don’t view her buying in as a bullish indicator. She’s welcome to do so, but I don’t get encouraged by it. Her track record isn’t great.

$NTLA CW is gonna blow up the shorts that's for sure... She's done it with $TSLA ... See it happening here again... 🤔🤔🤔

$NTLA By the time finds an alternative and does any trials that will be at least 5 years from now... By that time the most HAE patients will be cured by Lonvo-Z 😎😎😎

$NTLA the daily pill Oraldeyo for HAE retails at $1700 per pill! Cheaper wholesale, but insurance companies are still looking at 500K per year! Lonovo-z is onetime, but with 4 to 6 times that cost - so thats recoverable in 4-6 years. Intellia is apparently working on payment agreements, especially for situations where insurance companies change - it’s likely they will figure something out. From the patient perspective - what would you prefer if the insurance is going to pay for the pill or the one time treatment? Given the steep cost of the pill why would I want to take on the uncertainty of high insurance payments every year through the rest of my life? I would likely opt for the one time cure - and the strong interest in signing up for Clinical Trials is a very positive sign. Then there’s nex-z! Thats much larger, even if the issues are very similar. I think Gena Wang got this one wrong.

$NTLA Shorts continue to be relentless. Such a sad irony that a promising company that is working to improve life for humanity Is the target of such unending short selling.

$NTLA Hahaha, Barclay James Harvest, those greedy little bastards are your original market manipulators of the worst and most obvious kind. Great for anybody who thinks about opening a position in NTLA. I actually think that this is a bullish sign mid-term. Will stack up once the smoke clears. Laugh at it and be a little patient, at least that’s my strategy.

$NTLA Up 10% one day... Down 10% another day without news... We all know who is behind this crooked manipulation... Its the crooks behind the shorting... 😂😂😂

$NTLA I think whats interesting about gene editing that is different is for markets like HAE, once NTLA starts in on it, the market shrinks which sounds bad but it also means nobody will want to try to enter it because its getting smaller. Leaving all the pie for NTLA, same for ATTR or any functional cures

$NTLA CRISPR vs ART CRISPR is it known and proven method of editing genes as a method of treating illnesses or for other reasons. ART is a known and proven method of lowering the price of NTLA and other gene editing stocks so that people who know about them can purchase them more cheaply before major milestones happen. Personally, I took advantage of ART's effect on NTLA to add about 25% to my position.

$NTLA 1/2 a position.. let’s go 🐻 🐻 bring it down so I can 🐂 rush more tranche.. one time treatment with gene 🧬 editing? First move advantage playing out Happy Taco Tuesday y’all

$NTLA As of Q2 2026, ARK Investment Management holds 16,875,684 shares of Intellia Therapeutics (NTLA), valued at about $286 million, representing 1.85% of its portfolio

$NTLA Assuming AI fully commoditizes the genetic "scissors" (the enzymes), delivery technology becomes the ultimate bottleneck and holds nearly all the economic cards. Intellia isn’t just an enzyme company; they are a recognized leader in in vivo LNP delivery. Their proprietary LNP platform successfully achieved a historic 93% reduction in disease-causing liver proteins in clinical trials. They are heavily insulated from the AI threat because their delivery tech is world-class and already proven in humans [Written by specific prompts to Gemini]

$NTLA technically the Claude discovery should help biotech stocks go up as it improves their potential with the help of AI. Oh well, let the market move as it wants.